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A key characteristic that distinguishes survival analysis from other statistics 
fields is that survival data are usually censored or incomplete in some way. The event 
time is interval-censored when the exact event time is unknown and the event occurs 
within some interval of time. 
The purposes of this study included: developed an easy-to-use code for interval-
censored survival data with both fixed and time-dependent covariates; conducted 
extensive simulations to investigate the robustness of the interval-censored survival 
analysis with inaccurate time bounds and time-dependent covariates, particularly under 
noninformative censoring and informative censoring; conducted a real data analysis 
using the ACTG 175 data to investigate the robustness of findings under inaccurate time 
bounds.  
The likelihood approach was used to draw inferences about the unknown 
parameters. The parameter estimates and standard errors were obtained; confidence 
intervals were constructed. The findings for simulations demonstrated that for both 
noninformative censoring and informative censoring, parameter estimates and coverage 
probability were more robust against deviations from the true time bounds for regression 
coefficients of the fixed and time-dependent covariates than for general hazard function 
parameters. The findings for real data analysis demonstrated that for both 
noninformative censoring and informative censoring, the estimates and p-values for the 




This study was the first to develop the code for interval-censored survival data 
with both fixed and time-dependent covariates, and was the first to investigate the 
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Survival Data Analysis 
The statistical analysis of what are referred to as lifetime, survival time, or 
failure time data is an important topic in various fields and the applications of lifetime 
or survival time methodology range from examinations of the durability of 
manufactured items to studies and treatments of human diseases (Lawless, 2011). 
Survival analysis is used in many areas for analyzing data involving the times of 
transition among several states or conditions (Leung, Elashoff, & Afifi, 1997). 
Survival analysis is also called lifetime data analysis, time to event analysis, reliability 
and event history analysis, depending on the focus and the type of application (Leung 
et al., 1997; Prinja, Gupta, & Verma, 2010).  
In some instances, the events are actual deaths of individuals and “lifetime” 
referred to the length of life measured from some particular starting point. In other 
instances, terms such as “lifetime”, “death”, or “failure” denote the event of interest 
and are used in a figurative sense (Lawless, 2011).  
A key characteristic that distinguishes survival analysis from other statistics 
fields is that survival data are usually censored or incomplete in some way (Leung et 
al., 1997). There are three types of censoring, left censoring, right censoring, and 
interval censoring. 





The event times are censored when they are not observed accurately (Sparling, 
Younes, Lachin, & Bautista, 2006). In clinical trials, censoring usually occurs when 
information on time to outcome event is unavailable for all participants, and 
observations are censored when information on time to event is unavailable due to loss 
to follow-up or non-occurrence of outcome event before the trial end (Prinja et al., 
2010).  
The event time is right-censored when follow-up is curtailed without observing 
the event (Sparling et al., 2006). In clinical trials, an observation is considered right-
censored if the person was alive at study termination or was lost to follow-up at any 
time during the study (Leung et al., 1997). 
The event time is left-censored when the event occurs at some unknown time 
prior to an individual’s inclusion in a cohort (Sparling et al., 2006). In clinical trials, 
an observation is considered left-censored if the person had been on risk for disease 
for a period before entering the study (Prinja et al., 2010).  
The event time is interval-censored when the event occurs within some interval 
of time, but the exact event time is unknown (Sparling et al., 2006). Interval censoring 
can occur when observing a value requires follow-ups or inspections. Interval 
censoring occurs frequently in epidemiological, financial, sociological, and clinical 
(especially HIV and cancer) studies where the event of interest is known only to occur 
within an interval induced by periodic monitoring (Song & Ma, 2008; Zeng, Mao, & 
Lin, 2016). Practically, most observational studies dealing with non-lethal outcomes 
have periodic examination schedules and are interval-censored (Prinja et al., 2010; 





Right censoring (where the upper bound is infinity) and left censoring (where 
the lower bound is 0) can be considered as special cases of interval censoring. 
Therefore, the more general type of censoring (i.e., interval censoring) was focused in 
this project. This project conducted interval-censored survival analysis with time-
dependent covariates. 
Time-dependent Covariates 
In many instances, factors or covariates affecting an individual’s lifetime may 
vary over time, and we refer to them as time-dependent covariates (Lawless, 2011). 
For example, in a study which investigated the age at which smokers develop chronic 
diseases, the type and level of smoking for each participant can vary over time and are 
considered as time-dependent covariates. A lifetime’s relationship to covariates cannot 
be discussed without considering the values the covariates take over time; a generally 
useful approach is to consider the hazard function at time t conditional on previous 
covariate values (Lawless, 2011).  
In this project, the interval-censored survival analysis with time-dependent 
covariates were conducted under two scenarios, noninformative censoring and 
informative censoring. 
Noninformative Censoring and Informative Censoring 
Most studies assumed that the examination time and lifetime of interest are 
completely independent (e.g., Groeneboom & Wellner, 1992) or conditionally 
independent given covariates (e.g., Rossini & Tsiatis, 1996). This is known as the 
assumption of noninformative censoring. Chen, Lu, Chen, and Hsu (2012) suggested 





examination time is considered informative censoring. Such data may occur in many 
fields including epidemiological and medical studies.  
Dettoni, Marra, and Radice (2020) mentioned that censoring is independent 
when the hazard rate of the event of interest for the censored observations is equal to 
the hazard rate for the uncensored observations, otherwise censoring is dependent; 
censoring is informative or dependent when the censoring times contain information 
on the parameters of the distribution of the event variable (e.g., Kalbfleisch & 
Prentice, 2002). Ranganathan and Pramesh (2012) stated that censoring in survival 
analysis should be noninformative, which means participants who drop out of the 
study should do so due to reasons unrelated to the study, while informative censoring 
occurs when participants are lost to follow up due to reasons related to the study. 
Although informative censoring has been well-studied in the survival analysis (e.g., 
Chen et al., 2012; Leung et al., 1997; Emura & Chen, 2018), the specific study which 
analyzes the problem of informative censoring is scarce, even though ignoring it may 
cause detrimental consequences on inferential conclusions (e.g., Lu & Zhang, 2012).  
For this project, the analysis of interval-censored data was studied under both 
noninformative and informative censoring scenarios, using both simulations and the 
real data. 
The Real Data - ACTG 175 Data 
In real life, we may not be able to record the exact event time. For example, in 
the real data of the AIDS Clinical Trial Group (ACTG) 175 (e.g., Hammer et al., 
1996), time to progression to AIDS may not be accurately observed. Some previous 





Robins, 2002), while some studies considered the data as interval-censored (e.g., Song 
& Ma, 2008; Song & Wang, 2017; Wen, 2012; Wen & Chen, 2014). Several previous 
studies (e.g., Hammer et al., 1996; Huang & Zhang, 2008; Scharfstein & Robins, 
2002; Song, Davidian, & Tsiatis, 2002; Song & Ma, 2008; Song & Wang, 2017; Wen, 
2012; Wen & Chen, 2014) analyzing ACTG 175 data were discussed below. 
Hammer et al. (1996) evaluated treatment with either a single nucleoside or 
two nucleosides in HIV-1 infected adults whose CD4 cell counts were between 200 
and 500 per cubic millimeter. The ACTG 175, a randomized clinical trial that 
compares monotherapy with zidovudine or didanosine with combination therapy with 
zidovudine and didanosine or zidovudine and zalcitabine in HIV-1 infected adults with 
CD4 cell counts between 200 and 500 per cubic millimeter, was used in this study. 
The primary study end point was a decline in CD4 cell count of at least 50 percent, or 
an event indicating progression to AIDS or death. The variables involved in the 
analysis included gender, age, race, homosexuality, hemophilia, intravenous drug use, 
Karnofsky score, symptomatic HIV infection, previously received antiretroviral 
therapy, and CD4 cell count. Patients were examined at weeks 2, 4, and 8 and then 
every 12 weeks, with CD4 cell counts determined from week 8 onward. The results 
demonstrated that treatment with zidovudine alone was inferior to each of the other 
three treatments. Antiretroviral therapy can improve survival in patients with CD4 cell 
counts from 200 to 500 per cubic millimeter and such therapy can confer a survival 
benefit in a population with intermediate-stage disease.  
Patients were examined at weeks 2, 4, and 8 and then every 12 weeks, with 





counts were conducted every 12 weeks and the progression to AIDS depends on the 
CD4 cell counts, the event time should be considered as interval-censored. As a result, 
the analysis using models for right-censored data on the ACTG 175 data should be 
viewed as an approximation, and the accuracy of such approximation needs to be 
evaluated. In addition, if the periodic examination schedules for patients were 
followed exactly, then the censoring should be noninformative; however, in practice 
there might be factors that affect the examination date and the event time 
simultaneously which will result in informative censoring. 
Scharfstein and Robins (2002) also analyzed the ACTG 175 data as right-
censored data and developed a method for estimating the survival curve of a 
continuous survival time random variable. The method allowed for adjustment of 
informative censoring due to measured prognostic factors for time-to-event and 
censoring. In the ACTG 175 data, baseline variables included gender, age, race, 
ethnicity, CD4 cell count, Karnofsky score, prior use of antiretroviral therapy, 
symptomatic HIV infection, homosexuality, hemophilia and intravenous drug use. The 
variables used in the analysis included CD4 count, age, intravenous drug use, 
Karnofsky score, and symptomatic HIV infection. One finding was that subjects who 
had lower time-dependent CD4, were younger, were intravenous drug users and had 
lower baseline Karnofsky scores were more likely to be censored. 
Song et al. (2002) mentioned that time-dependent covariates are generally 
observed intermittently and are subject to error. They defined a joint longitudinal-
survival model with multiple time-dependent covariates measured at potentially 





conditional score approach which was for a single time-dependent covariate and 
required no assumption on the distribution of the random effects to multiple time-
dependent covariates. Song et al. (2002) used this approach to handle mismeasured 
covariates. The approach was illustrated via simulations and demonstrated by 
application to the ACTG 175 data. The variables included in the ACTG 175 data 
analysis were treatment, CD4 count, and CD8 count. Application of the approach 
showed that it is accessible for routine use and leads to reliable inference. 
Although both studies used the conditional score approach to handle 
mismeasured covariates, the study of Song et al. (2002) generalized the conditional 
score approach to multiple time-dependent covariates to handle mismeasured 
covariates, while the study of Song and Ma (2008) proposed a multiple data 
augmentation approach that can convert interval-censored data into right-censored 
data and then employed the conditional score approach, which was developed for 
analyzing right-censored data, to handle mismeasured covariates. The goal of the 
study of Song and Ma (2008) was to fill in the gap between methodologies for 
analyzing interval-censored data without mismeasured covariates and methodologies 
for analyzing right-censored data with mismeasured covariates. The performance of 
the multiple augmentation approach was assessed via simulation studies and the 
ACTG 175 data. The ACTG 175 data was analyzed as interval-censored data with 
mismeasured covariates. The variables used in the analysis included CD4 count and 
treatment. The findings showed that this approach had satisfactory empirical 
performance for interval-censored data. Song and Ma (2008) mentioned that this 





additive risk model, and that the conditional score approach can be replaced by other 
error-dealing approaches for right-censored data, such as correction approaches. 
The study of Song and Wang (2017) also used the conditional score approach 
to handle mismeasured covariates. However, different from the study of Song et al. 
(2002) and the study of Song and Ma (2008), Song and Wang (2017) proposed a 
partially time-varying coefficient proportional hazards model to explore the 
associations between the hazard of failure and covariates (time-varying covariates and 
fixed covariates). The coefficients were estimated using a polynomial spline approach, 
and the corrected score and conditional score approaches were used to deal with 
mismeasured covariates. The proposed model was assessed by simulations and applied 
to the ACTG 175 data to explore the temporal dynamics of the effect of treatment and 
CD4 counts on time to AIDS or death. The variables included in the model were 
treatment and CD4 count. Although both corrected score and conditional score 
approaches were asymptotically equivalent, the conditional score approach was 
recommended for its better finite sample performance. The proposed approach will 
have applicability in a wide range of studies for dealing with survival data with 
longitudinal mismeasured covariates. The proportional hazards model may be 
generalized to include functions of the random effects by analogy to Song et al. 
(2002). 
Similar to the study of Song and Ma (2008), which analyzed general interval-
censored data with mismeasured covariates, the study of Wen (2012) also analyzed 
general interval-censored data with mismeasured covariates. However, while Song and 





augmentation approach and employed the conditional score approach to handle 
mismeasured covariates, Wen (2012) described a semiparametric maximum likelihood 
(SPML) method for analyzing general interval-censored data with mismeasured 
covariates under the proportional hazards model, and proposed a stable and efficient 
computation algorithm for computing the SPML estimators. The proposed method 
was illustrated via simulations and with the ACTG 175 data. The primary goal of the 
ACTG 175 data analysis was to address the effects of baseline CD4 count and 
treatment on the time to AIDS or death in antiretroviral-naive patients. The covariates 
included in the analysis were CD4 count and treatment. The proposed approach can be 
applied to other semiparametric models, such as the proportional odds model. 
Although the studies of Song et al. (2002), Song and Ma (2008), Song and 
Wang (2017), and Wen (2012) also handled mismeasured covariates, the study of Wen 
and Chen (2014) was different. Wen and Chen (2014) proposed a functional inference 
method under the semiparametric proportional odds model for interval-censored 
survival data with mismeasured covariates. The approach used the working 
independence strategy to handle general interval-censored data and used the 
conditional score approach to handle mismeasured covariates. The proposed working 
independence conditional score approach was illustrated via simulations and the 
ACTG 175 data. The variables used in the analysis of ACTG 175 data included CD4 
count and treatment. Wen and Chen (2014) suggested some future directions such as 
extending the proposed approach to more general regression models than the 
proportional odds model and developing a functional modeling approach assumption 





Another study analyzing the ACTG 175 data (Huang & Zhang, 2008) proposed 
an estimation method for the bivariate proportional hazards model for competing risks. 
The copula approach was used to do sensitivity analysis for the Cox proportional 
hazards models. The joint modeling was used to address informative censoring. By 
this approach, the joint distribution of the survival time and censoring time is assumed 
to be a function of their marginal distributions. Huang and Zhang (2008) used this 
approach to assess the effect of informative censoring on the parameter estimates. The 
proposed approach was assessed by simulation studies and applied to the ACTG 175 
data. In the ACTG 175 data analysis, covariates were selected using a stepwise 
selection algorithm. A total of nine variables were selected for the analysis, including 
treatment, hemophilia, symptomatic HIV infection, gender, intravenous drug use, age, 
race, prior antiretroviral therapy, and CD4 count. 
The ACTG 175 data was also analyzed in the present study and the robustness 
of findings was investigated. The details of the present study were described below.  
Present Study 
In real life, we may not be able to record the exact event time or the accurate 
lower bound and upper bound for interval-censored survival data. For example, in the 
ACTG 175 data, the examinations of CD4 cell counts may not be conducted exactly 
every 12 weeks, and the time bounds may be affected by unobservable event time, 
which may result in inaccurate time bounds. If this is the case, the estimates as well as 
standard errors may not be calculated consistently, which may affect the accuracy of 
the findings. In this project, the impact of inaccurate time bounds on the analysis of 





censoring scenarios, using simulations and the real data. The purposes of the present 
study included:  
• Developed an easy-to-use code for interval-censored survival data with both 
fixed and time-dependent covariates.  
• Conducted extensive simulations to investigate the robustness of the interval-
censored survival analysis with inaccurate time bounds and time-dependent 
covariates, particularly under noninformative censoring and informative 
censoring. 
• Conducted a real data analysis using the ACTG 175 data to investigate the 
robustness of findings under inaccurate time bounds. 
This study was the first to develop the code for interval-censored survival data 
with both fixed and time-dependent covariates, and was the first to investigate the 
robustness of the interval-censored survival analysis under inaccurate time bounds. 
This study contributed to the research literature about the topic and contributed to the 










Data Setting  
The data consists of independently and identically distributed (i.i.d.) 
measurements from 𝑛 subjects. Each subject has a sequence of visit times, a vector of 
fixed covariates, a vector of time-dependent covariates, and an event time. 
Specifically, for subject 𝑖 = 1, …, 𝑛, let 𝜏𝑖,1 < ⋯ < 𝜏𝑖,𝐽𝑖 be a random sequence of visit 
times, where 𝐽𝑖 denotes the total number of visits for the ith subject. For convenience, 
let 𝜏𝑖,𝐽𝑖+1 = ∞. The first visit is at 𝜏𝑖,1 = 0, the beginning of the study. 
Let 𝑍𝑖 = (𝑍𝑖,1, …, 𝑍𝑖,𝑝)
T be a vector of p fixed covariates for the ith subject 
measured at the first visit. Let 𝑌𝑖,𝑗 = (𝑌𝑖,𝑗,1, ... , 𝑌𝑖,𝑗,𝑞)
T be a vector of q time-dependent 
covariates measured at the jth visit. The value of each time-dependent covariate is 
assumed to be constant within each interval (𝜏𝑖,𝑗,  𝜏𝑖,𝑗+1], for 𝑗 = 1, …, 𝐽𝑖. So, the 
vector of time-dependent covariates at time 𝑡 > 0 can be written as 
𝑌𝑖 (𝑡) = ∑ 𝑌𝑖,𝑗𝐼(𝜏𝑖,𝑗
𝐽𝑖
𝑗=1
< 𝑡 ≤ 𝜏𝑖,𝑗+1). 
The event time is denoted as 𝑋𝑖. The complete data for the ith subject consists 
of 𝐽𝑖, 𝜏𝑖,𝑗, 𝑍𝑖, 𝑌𝑖 (𝑡), and 𝑋𝑖. We may fail to observe the complete data due to the 
presence of censoring. The observed data for the ith subject consists of 𝑍𝑖, 𝑌𝑖 (𝑡), the 





then 𝛿𝑖 = 1 and 𝐿𝑖 = 𝑈𝑖 = 𝑋𝑖; otherwise, 𝛿𝑖 = 0, and 𝐿𝑖 and 𝑈𝑖 are the two adjacent 
visit times that have the event time 𝑋𝑖 in between, and can be written as Equation 1: 
𝐿𝑖 = ∑ 𝜏𝑖,𝑗𝐼(𝜏𝑖,𝑗
𝐽𝑖
𝑗=1
< 𝑋𝑖 ≤ 𝜏𝑖,𝑗+1) 
and Equation 2: 
𝑈𝑖 = ∑ 𝜏𝑖,𝑗+1𝐼(𝜏𝑖,𝑗
𝐽𝑖
𝑗=1
< 𝑋𝑖 ≤ 𝜏𝑖,𝑗+1). 
This formula allows for left-, right-, and interval-censored observations. The 
observation is left-censored if 𝐿𝑖 = 0; the observation is right-censored if 𝑈𝑖 = ∞; the 
observation is interval-censored if 𝐿𝑖 > 0 and 𝑈𝑖 < ∞. 
 Let 𝛾 and 𝜂 be the coefficient vectors for the fixed and time-dependent 
covariates, 𝜃 be the intercept; 𝛾 is p-dimensional, 𝜂 is q-dimensional. With time-









where 𝛼 > 0 and 𝜅 are general hazard function parameters; the parameter vector 
𝜔 = (𝜃, 𝛾, 𝜅, 𝛼, 𝜂)𝑇. Specific values for 𝛼 and 𝜅 yield a specific distribution (Sparling 
et al, 2006). For instance, 𝜅 = 0 yields a Weibull hazard. With no time-dependent 
















the survival function is 
S𝑖(𝑡; 𝜔) = 𝑒
−Λ𝑖(𝑡;𝜔), 
the probability density function is 
𝑓𝑖(𝑡; 𝜔) = 𝜆𝑖(𝑡; 𝜔)𝑒
−Λ𝑖(𝑡;𝜔), 
and the cumulative distribution function is 
 𝐹𝑖(𝑡; 𝜔) = 1 − 𝑒
−Λ𝑖(𝑡;𝜔). 
Model 
The likelihood approach was used to draw inferences about the unknown 
parameters. The log-likelihood function can be expressed as 




where the parameter vector 𝜔 = (𝜃, 𝛾, 𝜅, 𝛼, 𝜂)𝑇. The estimator, ?̂?, was the maximizer 
of the log-likelihood function and was asymptotically normal. The R function optim 
with BFGS method (Nocedal & Wright, 1999) was used to calculate the maximizer. 
The R package, numDeriv, was used to calculate the Hessian matrix of the negative 
log-likelihood. The estimated variance was the diagonal of the inverse of the Hessian 
matrix and the standard errors of the estimates equaled the square root of the estimated 
variance. The 95% confidence intervals were constructed using estimates plus and 
minus 1.96 times standard errors. 
Development of an Easy-to-Use Implementation 
Existing software provide limited support in fitting regression models with 





survreg function in R can be used for left, right, or interval-censored data, but it can 
only be applied to fixed covariates; the coxph function can be used for both fixed and 
time-dependent covariates, but it can only be used for right-censored data. To facilitate 
the study of the impact of inaccurate time bounds, I developed my own code for 
interval-censored survival data which included both fixed and time-dependent 
covariates.  
Simulation Studies 
I conducted simulations to see estimate difference when time bounds of the 
intervals were not exactly observed or accurately recorded. In the simulated data, the 
lower bound of the interval is 𝐿𝑖, and the upper bound of the interval is 𝑈𝑖. The 
interval-censored variable is 1 − 𝛿𝑖. The time-independent variables are 𝑍𝑖. The time-
dependent variables are 𝑌𝑖 (𝑡).  
In the first scenario, 500 simulated datasets were generated. Each simulated 
dataset consisted of 1000 i.i.d. observations and included only fixed covariates, 𝑍𝑖,1 
and 𝑍𝑖,2. The covariate 𝑍𝑖,1 was a normal random variable with mean 0 and variance 1 
and 𝑍𝑖,2 was a binomial random variable with probability of 0.5. The lower bound of 
the interval 𝐿𝑖 as well as the upper bound of the interval 𝑈𝑖 were elements of the 
vector of 𝜏𝑖,𝑗, which was defined as [0, 10] evenly visit 10000 times. 𝐿𝑖 and 𝑈𝑖 were 
obtained using Equation 1 and 2, respectively. The event time, 𝑋𝑖, was S𝑖
−1(𝑄𝑖), 
where 𝑄𝑖 was i.i.d. uniform (0, 1). All the observations were interval-censored. The 






In the second scenario, 500 simulated datasets were generated. Each simulated 
dataset consisted of 1000 i.i.d. observations and included both fixed covariates, 𝑍𝑖,1 
and 𝑍𝑖,2,  and time-dependent covariate, 𝑌𝑖 (𝑡). The fixed covariate 𝑍𝑖,1 was a normal 
random variable with mean 0 and variance 1 and 𝑍𝑖,2 was a binomial random variable 
with probability of 0.5. The time-dependent covariate 𝑌𝑖 (𝑡) = 𝐼 (𝑡 > 𝑊𝑖), where 𝑊𝑖 
was i.i.d. uniform (0, 2). The lower bound of the interval 𝐿𝑖 as well as the upper bound 
of the interval 𝑈𝑖 were elements of the vector of 𝜏𝑖,𝑗, which was defined as [0, 13] 
evenly visit 10000 times. 𝐿𝑖 and 𝑈𝑖  were obtained using Equation 1 and 2, 
respectively. The event time, 𝑋𝑖, was S𝑖
−1(𝑄𝑖), where 𝑄𝑖 was i.i.d. uniform (0, 1). All 
the observations were interval-censored. The true values for the six parameters, 
𝜃, 𝛾1, 𝛾2, 𝜅, 𝛼, 𝜂, were 0, 0.8, 0.8, 0, 2, and −0.5, respectively. 
In this study, extensive simulations were conducted to investigate the 
robustness of the interval-censored survival analysis with inaccurate time bounds and 
time-dependent covariates, particularly under the following two scenarios.  
1) noninformative censoring: 
The new lower bound and upper bound of interval were defined as follows: 
new 𝐿𝑖 = 𝐿𝑖 𝐾𝐿𝑖 
new 𝑈𝑖 = 𝑈𝑖 𝐾𝑈𝑖 
where 𝐾𝐿𝑖 was drawn from a uniform distribution on [1/ 𝑀, 1] and 𝐾𝑈𝑖 was 
drawn from a uniform distribution on [1, 𝑀] and 𝑀 ≥ 1 was a tuning parameter which 
was a sequence of 20 numbers between 1 and 10. 
2) informative censoring: 





new 𝐿𝑖 = 𝐿𝑖 𝐾𝐿𝑖 
new 𝑈𝑖 = 𝑈𝑖 𝐾𝑈𝑖 
where 𝐾𝐿𝑖 was drawn from a uniform distribution on [1/𝑀𝐿𝑖, 1] and 𝐾𝑈𝑖 was 
drawn from a uniform distribution on [1, 𝑀𝑈𝑖]; 𝑀𝐿𝑖 ≥ 1 as well as 𝑀𝑈𝑖 ≥ 1 was a 
tuning parameter that was a function of 𝐿𝑖 and 𝑈𝑖. For example, 𝑀𝐿𝑖 = 1 +
(𝑀 − 1) 
𝐿𝑖
𝑚𝑒𝑎𝑛(𝐿𝑖)
, 𝑀𝑈𝑖 = 1 + (𝑀 − 1) 
𝑈𝑖
𝑚𝑒𝑎𝑛(𝑈𝑖)
, and 𝑀 was a tuning parameter as in 
the noninformative censoring scenario. 
The method described in Chapter 2 was applied to obtain the parameter 
estimates. Then the bias, the standard error, the mean squared error (i.e., the average 
squared difference between the estimated values and the true value), the coverage 
probability (i.e., the probability that a procedure for constructing random regions will 
produce an interval containing the true value) were calculated for each parameter. The 
programming language was R.  
Real Data Application 
The ACTG 175 (e.g., Hammer et al., 1996) was a randomized clinical trial to 
compare monotherapy with zidovudine or didanosine with combination therapy with 
zidovudine and didanosine or zidovudine and zalcitabine in HIV-1 infected adults with 
CD4 cell counts between 200 and 500 per cubic millimeter. The primary study end 
point was a decline in CD4 cell count of at least 50 percent, or an event indicating 
progression to AIDS or death. Patients were examined at weeks 2, 4, and 8 and then 
every 12 weeks, with CD4 cell counts determined from week 8 onward. This dataset 
had 2139 observations. The data included the following time-dependent covariate, cd4 





as treat (treatment), karnof (Karnofsky score), symptom (symptomatic HIV infection), 
etc. 
The variable days referred to the number of days until the first occurrence of a 
decline in CD4 T cell count of at least 50 percent, or an event indicating progression to 
AIDS, or death. According to the study of Hammer et al. (1996), the examinations of 
CD4 cell counts were conducted every 12 weeks. Thus, when interval-censored the 
upper bound of the interval was the variable days and the lower bound of the interval 
was days − 12 × 7; if days −12 × 7 < 0, then the lower bound of the interval was set 
to be 0. When right-censored the lower bound of the interval was days and the upper 
bound of the interval was infinite.  
The method described in Chapter 2 was applied to the ACTG 175 data and the 
parameter estimates, standard errors, and p-values were obtained. 
For real data analysis, the robustness of findings (estimates, standard errors, 
and p-values) under different variations of time bounds were investigated. 𝑀 was an 
upper bound for the errors in the time bounds which was a sequence of 20 numbers 
between 1 and 10, so we investigated if different choices of 𝑀 might affect the 
findings. 










 In the simulations, bias, standard error, mean squared error, and coverage 
probability of 95% confidence interval for each parameter were reported for each of 
the 20 M values for the simulated dataset including both fixed and time-dependent 
covariates (i.e., scenario 2). Box plots were drawn for parameter estimates of each 
parameter across 20 M values for noninformative censoring and informative censoring 
of scenario 2 (see Figure 1). Scatter plots were drawn for coverage probability of 95% 
confidence interval across 20 M values for each parameter for noninformative 
censoring and informative censoring of scenario 2 (see Figure 2). 
Figure 1 showed that for both noninformative censoring and informative 
censoring, parameter estimates for 𝛾1, 𝛾2, and 𝜂 were more robust against change 
across 20 M values, but parameter estimates for 𝜃, 𝜅, and 𝛼 were not that robust 
against change across 20 M values. 
The average bias across 500 data sets for each parameter across 20 M values 
for scenario 2 were demonstrated in Table 1 for noninformative censoring and in 
Table 5 for informative censoring. We can see from Table 1 that for noninformative 
censoring, bias was more robust against change across 20 M values for 𝛾1, 𝛾2, and 𝜂 
than for 𝜃, 𝜅, and 𝛼. We can see from Table 5 that for informative censoring, bias was 





The average standard error across 500 data sets for each parameter across 20 M 
values for scenario 2 were demonstrated in Table 2 for noninformative censoring and 
in Table 6 for informative censoring. We can see from Table 2 and Table 6 that 
standard error slightly increased across M values for each parameter, for both 
noninformative censoring and informative censoring. 
The average mean squared error across 500 data sets for each parameter across 
20 M values for scenario 2 were demonstrated in Table 3 for noninformative censoring 
and in Table 7 for informative censoring. We can see from Table 3 that for 
noninformative censoring, mean squared error was more robust against change across 
20 M values for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼. We can see from Table 7 that for 
informative censoring, mean squared error was more robust against change across 20 
M values for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼. 
The coverage probability of 95% confidence interval across 20 M values for 
each parameter for scenario 2 were demonstrated in Table 4 for noninformative 
censoring and in Table 8 for informative censoring. Scatter plots were also drawn for 
coverage probability for noninformative censoring and informative censoring (see 
Figure 2). We can see from Table 4 and Figure 2 (a) that for noninformative 
censoring, coverage probability was more robust against change across 20 M values 
for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼. We can see from Table 8 and Figure 2 (b) that 
for informative censoring, coverage probability was more robust against change across 
20 M values for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼. 
Additionally, box plots were drawn for parameter estimates of each parameter 





simulated dataset including only fixed covariates (i.e., scenario 1). See Figure 3 for 
box plots. Scatter plots were drawn for coverage probability of 95% confidence 
interval across 20 M values for each parameter for noninformative censoring and 
informative censoring of scenario 1 (see Figure 4). 
Figure 3 and Figure 4 demonstrated that for noninformative censoring, 
parameter estimates and coverage probability for 𝛾1 and 𝛾2 were more robust against 
change across 20 M values, but parameter estimates and coverage probability for 𝜃, 𝜅, 
and 𝛼 were not that robust against change across 20 M values; for informative 
censoring, parameter estimates and coverage probability for 𝛾1 and 𝛾2 were more 
robust against change across 20 M values, but parameter estimates and coverage 
probability for 𝜃, 𝜅, and 𝛼 were not robust against change across 20 M values. 
To summarize, the findings showed that for noninformative censoring of 
scenario 2, parameter estimates as well as coverage probability were more robust 
against change across M values for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼, which were not 
that robust against change across M values; for informative censoring of scenario 2, 
parameter estimates as well as coverage probability were more robust against change 
across M values for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼, which were not robust against 
change across M values. Moreover, for noninformative censoring of scenario 1, 
parameter estimates as well as coverage probability were more robust against change 
across M values for 𝛾1 and 𝛾2 than for 𝜃, 𝜅, and 𝛼, which were not that robust against 
change across M values; for informative censoring of scenario 1, parameter estimates 
as well as coverage probability were more robust against change across M values for 





In both scenario 2 and scenario 1, the parameter estimates and coverage probability for 
𝛼 were more robust against change across M values for noninformative censoring than 
for informative censoring. 
In the scenarios considered in this simulation study, noninformative censoring 
is almost irrelevant to survival time, so as M value changed, for noninformative 
censoring, both scale and shape parameters (𝜃, 𝜅, and 𝛼) changed but were not as 
severe as that for informative censoring. Informative censoring is related to survival 
time, as M value changed, the new lower bound and upper bound of interval had 
relationship with the original lower bound and upper bound of interval, so both scale 
and shape changed for informative censoring. Since 𝜃 affects scale, 𝜅 affects scale and 
shape, 𝛼 affects shape, thus for noninformative censoring (both scale and shape 
changed as M changed but were not as severe as that for informative censoring), the 
parameter estimates and coverage probability for 𝜃, 𝜅, and 𝛼 were not very robust 
against change across M values, but for 𝛼 were kind of more robust against change 
across M values than for informative censoring. For informative censoring (both scale 
and shape changed as M changed), parameter estimates and coverage probability for 𝜃, 
𝜅, and 𝛼 were not robust against change across M values. In addition, noninformative 
censoring has no relationship with fixed and time-dependent covariates, thus for 
noninformative censoring, the parameter estimates as well as coverage probability for 
𝛾1, 𝛾2, and 𝜂 were robust against change across M values. The informative censoring 
scenario considered in this study has no strong relationship with fixed covariates and 





coverage probability for 𝛾1, 𝛾2, and 𝜂 were also robust against change across M 
values. 
Real Data Analysis 
Some previous studies analyzing ACTG 175 data only used treatment and cd4 
counts variables in the analysis (e.g., Song & Ma, 2008; Song & Wang, 2017; Wen, 
2012; Wen & Chen, 2014), so the real data analysis in this study first used treat as 
fixed covariate and cd4 as time-dependent covariate. The estimates, standard errors, 
and p-values under different variations of time bounds were obtained for the fixed 
covariate, treat, and the time-dependent covariate, cd4. 
The estimates, standard errors, test statistics (estimates/ standard errors), and p-
values across 20 M values for the treat and cd4 variables in ACTG 175 were 
demonstrated in Table 9 for noninformative censoring and in Table 10 for informative 
censoring. We can see from Table 9 that for noninformative censoring, the estimates 
for treat and cd4 were relatively robust against change across M values; the p-values 
for treat and cd4 were also relatively robust against change across M values. We can 
see from Table 10 that for informative censoring, the estimates for treat and cd4 were 
very robust against change across M values; the p-values for treat and cd4 were also 
very robust against change across M values. The noninformative censoring has no 
relationship with fixed and time-dependent covariates, thus for noninformative 
censoring, the estimates for treat and cd4 were robust against change across M values. 
The informative censoring scenario considered in this study has no strong relationship 
with fixed covariates and time-dependent covariates, thus for informative censoring, 





estimates for treat and cd4 were all negative for noninformative and informative 
censoring and moved towards zero. Moreover, the p-values for treat and cd4 were all 
significant across M values for noninformative and informative censoring. The 
negative and significant estimates indicated longer survival time and event occurred 
later. Besides, the estimates under informative censoring were more robust against 
change across M values, compared to the estimates under noninformative censoring, 
which was worth further investigation. 
In addition to the treatment and cd4 variables, some previous studies analyzing 
ACTG 175 data also included some other variables in the analysis, such as Karnofsky 
score and symptomatic HIV infection (e.g., Hammer et al.,1996; Scharfstein & 
Robins, 2002), so the real data analysis in this study also included some more 
covariates, karnof and symptom, to see if there would be any differences in the 
robustness of findings. The estimates, standard errors, and p-values under different 
variations of time bounds were obtained for the fixed covariates, treat, karnof, and 
symptom, and the time-dependent covariate, cd4. The findings for this analysis when 
more covariates were included were compared with the findings for the analysis when 
only treat and cd4 were used. 
The estimates, standard errors, test statistics (estimates/ standard errors), and p-
values across 20 M values for the treat, karnof, symptom and cd4 variables in ACTG 
175 were demonstrated in Table 11 and Table 12 for noninformative censoring and in 
Table 13 and Table 14 for informative censoring. We can see from Table 11 and 12 
that for noninformative censoring, the estimates as well as p-values for treat and cd4 





similar to those in the analysis when only treat and cd4 were used. For example, when 
only treat and cd4 were used, the range of estimates for treat were around (-0.334, -
0.042); when more covariates were included, the range of estimates for treat were 
around (-0.349, -0.057); the p-values for treat and cd4 in both analyses were all less 
than 0.05 and significant. We can see from Table 13 and 14 that for informative 
censoring, the estimates as well as p-values for treat and cd4 were very robust against 
change across M values, and were similar to those in the analysis when only treat and 
cd4 were used. For example, when only treat and cd4 were used, the range of 
estimates for treat were around (-0.334, -0.282); when more covariates were included, 
the range of estimates for treat were around (-0.349, -0.298); the p-values for treat and 
cd4 in both analyses were all less than 0.0001 and significant. The estimates for treat 
and cd4 were all negative for noninformative and informative censoring. Moreover, 
the p-values for treat and cd4 were all significant across M values for noninformative 
and informative censoring. The negative estimates indicated longer survival time and 
event occurred later. The estimates for symptom were all positive for noninformative 
and informative censoring, which indicated shorter survival time with symptomatic 
HIV infection. Still, the estimates under informative censoring were more robust 
against change across M values, compared to the estimates under noninformative 










Bias across 20 M Values for Each Parameter for Noninformative Censoring of 
Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 -0.0072 -0.0213 0.0043 0.0026 0.0021 0.0006 
1.47 -0.0498 -0.0847 0.0042 0.0016 0.0005 -0.0023 
1.95 -0.1099 -0.1420 0.0202 0.0076 0.0047 -0.0036 
2.42 -0.1755 -0.1942 0.0402 0.0153 0.0158 -0.0057 
2.89 -0.2400 -0.2433 0.0602 0.0227 0.0210 -0.0026 
3.37 -0.3083 -0.2945 0.0699 0.0258 0.0274 0.0012 
3.84 -0.3772 -0.3717 0.0767 0.0277 0.0296 -0.0002 
4.32 -0.4361 -0.4273 0.0916 0.0329 0.0321 0.0020 
4.79 -0.5072 -0.5267 0.0884 0.0317 0.0344 0.0059 
5.26 -0.5558 -0.5538 0.0994 0.0374 0.0365 0.0100 
5.74 -0.6248 -0.6685 0.0951 0.0356 0.0336 0.0182 
6.21 -0.6658 -0.6988 0.1125 0.0441 0.0433 0.0088 
6.68 -0.7418 -0.8837 0.0953 0.0339 0.0400 0.0163 
7.16 -0.7838 -0.9050 0.1086 0.0421 0.0423 0.0198 
7.63 -0.8210 -0.9772 0.1215 0.0467 0.0455 0.0155 
8.11 -0.8748 -1.0894 0.1171 0.0441 0.0436 0.0164 
8.58 -0.9234 -1.1863 0.1214 0.0461 0.0502 0.0269 
9.05 -0.9628 -1.2892 0.1242 0.0472 0.0424 0.0260 
9.53 -1.0103 -1.3817 0.1204 0.0445 0.0481 0.0326 










Standard Error across 20 M Values for Each Parameter for Noninformative 
Censoring of Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 0.0955 0.1782 0.1101 0.0549 0.0776 0.0799 
1.47 0.1031 0.2083 0.1173 0.0578 0.0805 0.0858 
1.95 0.1127 0.2453 0.1277 0.0622 0.0857 0.0933 
2.42 0.1213 0.2811 0.1379 0.0667 0.0908 0.1001 
2.89 0.1286 0.3161 0.1475 0.0707 0.0958 0.1063 
3.37 0.1346 0.3494 0.1556 0.0742 0.1000 0.1112 
3.84 0.1412 0.3933 0.1640 0.0775 0.1039 0.1155 
4.32 0.1464 0.4299 0.1719 0.0809 0.1076 0.1195 
4.79 0.1519 0.4813 0.1791 0.0838 0.1107 0.1223 
5.26 0.1546 0.5045 0.1847 0.0864 0.1140 0.1260 
5.74 0.1600 0.5673 0.1919 0.0892 0.1166 0.1280 
6.21 0.1631 0.5951 0.1980 0.0920 0.1199 0.1314 
6.68 0.1702 0.6941 0.2052 0.0942 0.1219 0.1326 
7.16 0.1726 0.7152 0.2112 0.0970 0.1247 0.1356 
7.63 0.1760 0.7744 0.2175 0.0994 0.1280 0.1384 
8.11 0.1804 0.8452 0.2238 0.1019 0.1303 0.1401 
8.58 0.1843 0.9123 0.2295 0.1043 0.1330 0.1417 
9.05 0.1887 0.9863 0.2355 0.1066 0.1348 0.1434 
9.53 0.1919 1.0552 0.2403 0.1085 0.1375 0.1455 










Mean Squared Error across 20 M Values for Each Parameter for Noninformative 
Censoring of Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 0.0081 0.0288 0.0106 0.0029 0.0059 0.0067 
1.47 0.0122 0.0482 0.0123 0.0033 0.0062 0.0077 
1.95 0.0234 0.0772 0.0149 0.0040 0.0072 0.0096 
2.42 0.0445 0.1163 0.0193 0.0047 0.0086 0.0110 
2.89 0.0739 0.1730 0.0242 0.0058 0.0093 0.0117 
3.37 0.1122 0.2144 0.0290 0.0065 0.0110 0.0125 
3.84 0.1617 0.3181 0.0333 0.0072 0.0121 0.0143 
4.32 0.2107 0.3967 0.0386 0.0087 0.0134 0.0134 
4.79 0.2807 0.5606 0.0417 0.0088 0.0143 0.0170 
5.26 0.3329 0.5881 0.0459 0.0099 0.0155 0.0170 
5.74 0.4164 0.8417 0.0462 0.0097 0.0145 0.0180 
6.21 0.4679 0.8738 0.0530 0.0113 0.0174 0.0186 
6.68 0.5827 1.4497 0.0554 0.0115 0.0187 0.0185 
7.16 0.6437 1.3686 0.0589 0.0121 0.0188 0.0198 
7.63 0.7096 1.8358 0.0680 0.0140 0.0198 0.0220 
8.11 0.7989 2.1821 0.0631 0.0124 0.0194 0.0216 
8.58 0.8902 2.6299 0.0749 0.0143 0.0219 0.0243 
9.05 0.9666 3.1198 0.0788 0.0154 0.0216 0.0230 
9.53 1.0641 3.5497 0.0745 0.0154 0.0213 0.0213 










Coverage Probability of 95% Confidence Interval across 20 M Values for Each 
Parameter for Noninformative Censoring of Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 0.964 0.970 0.978 0.944 0.940 0.944 
1.47 0.934 0.976 0.980 0.950 0.950 0.950 
1.95 0.860 0.974 0.958 0.942 0.950 0.940 
2.42 0.708 0.974 0.946 0.948 0.946 0.940 
2.89 0.554 0.972 0.928 0.936 0.950 0.944 
3.37 0.360 0.984 0.932 0.934 0.948 0.952 
3.84 0.204 0.986 0.938 0.940 0.944 0.946 
4.32 0.110 0.986 0.918 0.916 0.932 0.958 
4.79 0.068 0.992 0.920 0.908 0.936 0.942 
5.26 0.044 0.994 0.902 0.916 0.932 0.938 
5.74 0.022 0.998 0.922 0.950 0.962 0.926 
6.21 0.006 0.996 0.920 0.926 0.954 0.948 
6.68 0.008 0.998 0.924 0.926 0.948 0.934 
7.16 0.002 1.000 0.910 0.924 0.928 0.934 
7.63 0.000 1.000 0.904 0.928 0.944 0.928 
8.11 0.000 0.996 0.922 0.946 0.942 0.932 
8.58 0.000 0.998 0.910 0.928 0.934 0.916 
9.05 0.000 0.998 0.910 0.918 0.946 0.918 
9.53 0.002 0.996 0.920 0.924 0.944 0.944 










Bias across 20 M Values for Each Parameter for Informative Censoring of Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 -0.0072 -0.0213 0.0043 0.0026 0.0021 0.0006 
1.47 -0.0090 -0.0627 0.0073 0.0033 0.0027 0.0003 
1.95 -0.0020 -0.0342 0.0165 0.0204 0.0197 -0.0273 
2.42 -0.0213 -0.0283 0.0051 0.0290 0.0290 -0.0398 
2.89 -0.0520 -0.0399 -0.0118 0.0344 0.0316 -0.0442 
3.37 -0.0973 -0.0753 -0.0368 0.0332 0.0359 -0.0451 
3.84 -0.1433 -0.1204 -0.0628 0.0323 0.0321 -0.0404 
4.32 -0.1933 -0.1745 -0.0910 0.0266 0.0266 -0.0312 
4.79 -0.2325 -0.2144 -0.1096 0.0254 0.0258 -0.0304 
5.26 -0.2818 -0.2792 -0.1342 0.0204 0.0207 -0.0204 
5.74 -0.3272 -0.3511 -0.1559 0.0149 0.0147 -0.0177 
6.21 -0.3752 -0.4087 -0.1780 0.0107 0.0138 -0.0082 
6.68 -0.4114 -0.4627 -0.1917 0.0089 0.0083 0.0006 
7.16 -0.4548 -0.5508 -0.2157 0.0011 -0.0021 0.0066 
7.63 -0.4903 -0.6129 -0.2269 -0.0015 0.0006 0.0071 
8.11 -0.5264 -0.6710 -0.2414 -0.0054 -0.0049 0.0103 
8.58 -0.5630 -0.7384 -0.2551 -0.0086 -0.0048 0.0238 
9.05 -0.6028 -0.8353 -0.2715 -0.0145 -0.0145 0.0322 
9.53 -0.6282 -0.8970 -0.2818 -0.0175 -0.0210 0.0294 











Standard Error across 20 M Values for Each Parameter for Informative Censoring of 
Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 0.0955 0.1782 0.1101 0.0549 0.0776 0.0799 
1.47 0.1075 0.2138 0.1181 0.0587 0.0825 0.0883 
1.95 0.1161 0.2281 0.1227 0.0618 0.0877 0.0984 
2.42 0.1223 0.2420 0.1258 0.0642 0.0917 0.1055 
2.89 0.1268 0.2563 0.1280 0.0664 0.0948 0.1110 
3.37 0.1310 0.2757 0.1302 0.0682 0.0972 0.1147 
3.84 0.1345 0.2967 0.1318 0.0698 0.0990 0.1175 
4.32 0.1378 0.3197 0.1335 0.0711 0.1004 0.1195 
4.79 0.1406 0.3390 0.1352 0.0725 0.1020 0.1216 
5.26 0.1427 0.3649 0.1365 0.0736 0.1032 0.1226 
5.74 0.1460 0.3947 0.1384 0.0749 0.1041 0.1233 
6.21 0.1477 0.4180 0.1395 0.0759 0.1051 0.1240 
6.68 0.1499 0.4413 0.1413 0.0771 0.1061 0.1248 
7.16 0.1529 0.4781 0.1425 0.0777 0.1065 0.1252 
7.63 0.1554 0.5070 0.1444 0.0789 0.1077 0.1260 
8.11 0.1568 0.5313 0.1455 0.0797 0.1083 0.1265 
8.58 0.1590 0.5616 0.1471 0.0806 0.1093 0.1266 
9.05 0.1616 0.6036 0.1488 0.0816 0.1099 0.1263 
9.53 0.1640 0.6336 0.1502 0.0823 0.1103 0.1269 










Mean Squared Error across 20 M Values for Each Parameter for Informative 
Censoring of Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 0.0081 0.0288 0.0106 0.0029 0.0059 0.0067 
1.47 0.0103 0.0456 0.0121 0.0035 0.0068 0.0076 
1.95 0.0124 0.0540 0.0142 0.0044 0.0084 0.0107 
2.42 0.0129 0.0530 0.0139 0.0047 0.0088 0.0120 
2.89 0.0170 0.0664 0.0145 0.0055 0.0096 0.0140 
3.37 0.0243 0.0731 0.0156 0.0057 0.0108 0.0161 
3.84 0.0365 0.1024 0.0194 0.0058 0.0108 0.0156 
4.32 0.0542 0.1253 0.0233 0.0054 0.0107 0.0154 
4.79 0.0702 0.1463 0.0266 0.0054 0.0102 0.0160 
5.26 0.0977 0.2100 0.0340 0.0057 0.0108 0.0165 
5.74 0.1262 0.2746 0.0411 0.0059 0.0114 0.0148 
6.21 0.1589 0.3115 0.0472 0.0051 0.0108 0.0138 
6.68 0.1874 0.3717 0.0523 0.0056 0.0104 0.0156 
7.16 0.2274 0.5236 0.0633 0.0058 0.0110 0.0152 
7.63 0.2625 0.6209 0.0701 0.0062 0.0116 0.0167 
8.11 0.2992 0.7125 0.0759 0.0059 0.0114 0.0163 
8.58 0.3391 0.8280 0.0820 0.0061 0.0109 0.0168 
9.05 0.3866 1.0426 0.0924 0.0068 0.0123 0.0166 
9.53 0.4168 1.1711 0.0980 0.0068 0.0124 0.0173 










Coverage Probability of 95% Confidence Interval across 20 M Values for Each 
Parameter for Informative Censoring of Scenario 2 
M Parameter 
 𝜃 𝜅 𝛼 𝛾1 𝛾2 𝜂 
1.00 0.964 0.970 0.978 0.944 0.940 0.944 
1.47 0.966 0.966 0.970 0.950 0.954 0.956 
1.95 0.962 0.958 0.962 0.938 0.936 0.944 
2.42 0.968 0.962 0.962 0.940 0.952 0.952 
2.89 0.960 0.966 0.974 0.918 0.942 0.944 
3.37 0.902 0.972 0.970 0.936 0.948 0.930 
3.84 0.838 0.968 0.940 0.940 0.942 0.954 
4.32 0.740 0.984 0.918 0.952 0.962 0.944 
4.79 0.634 0.994 0.906 0.954 0.956 0.940 
5.26 0.482 0.990 0.842 0.958 0.948 0.950 
5.74 0.370 0.978 0.816 0.944 0.940 0.962 
6.21 0.240 0.990 0.762 0.958 0.954 0.964 
6.68 0.172 0.994 0.740 0.954 0.968 0.950 
7.16 0.120 0.990 0.670 0.954 0.950 0.956 
7.63 0.074 0.986 0.622 0.944 0.940 0.956 
8.11 0.040 0.982 0.610 0.952 0.942 0.940 
8.58 0.036 0.980 0.588 0.946 0.948 0.940 
9.05 0.018 0.970 0.548 0.954 0.946 0.938 
9.53 0.014 0.984 0.518 0.940 0.932 0.932 










Estimates, Standard Errors, Test Statistics, and P-values across 20 M Values for Treat 
and CD4 Variables in ACTG 175 for Noninformative Censoring 
M Treat CD4 
 Estimate SE Test P Estimate SE Test P 
1.00 -0.3338 0.0596 -5.5967 <0.0001 -1.1157 0.0749 -14.9004 <0.0001 
1.47 -0.2569 0.0524 -4.9052 <0.0001 -0.9993 0.0853 -11.7196 <0.0001 
1.95 -0.2000 0.0508 -3.9365 0.0001 -0.8625 0.1004 -8.5918 <0.0001 
2.42 -0.1159 0.0308 -3.7585 0.0002 -0.4179 0.0840 -4.9778 <0.0001 
2.89 -0.1161 0.0396 -2.9276 0.0034 -0.4609 0.1325 -3.4792 0.0005 
3.37 -0.1258 0.0381 -3.3057 0.0009 -0.4993 0.1034 -4.8272 <0.0001 
3.84 -0.0570 0.0219 -2.6061 0.0092 -0.2804 0.0753 -3.7250 0.0002 
4.32 -0.1026 0.0328 -3.1290 0.0018 -0.4184 0.0957 -4.3714 <0.0001 
4.79 -0.1253 0.0354 -3.5446 0.0004 -0.4682 0.0942 -4.9717 <0.0001 
5.26 -0.0612 0.0143 -4.2821 <0.0001 -0.2659 0.0214 -12.4245 <0.0001 
5.74 -0.0950 0.0356 -2.6716 0.0075 -0.3776 0.0950 -3.9753 0.0001 
6.21 -0.0421 0.0164 -2.5586 0.0105 -0.2312 0.0201 -11.4909 <0.0001 
6.68 -0.0675 0.0156 -4.3216 <0.0001 -0.2755 0.0226 -12.2082 <0.0001 
7.16 -0.0528 0.0225 -2.3466 0.0189 -0.3168 0.0829 -3.8194 0.0001 
7.63 -0.0677 0.0281 -2.4100 0.0160 -0.3130 0.0978 -3.1994 0.0014 
8.11 -0.0619 0.0250 -2.4727 0.0134 -0.2841 0.0718 -3.9563 0.0001 
8.58 -0.0642 0.0281 -2.2829 0.0224 -0.3248 0.0864 -3.7602 0.0002 
9.05 -0.1013 0.0383 -2.6471 0.0081 -0.4562 0.1265 -3.6064 0.0003 
9.53 -0.1037 0.0510 -2.0339 0.0420 -0.4057 0.1654 -2.4531 0.0142 






Estimates, Standard Errors, Test Statistics, and P-values across 20 M Values for Treat 
and CD4 Variables in ACTG 175 for Informative Censoring 
M Treat CD4 
 Estimate SE Test P Estimate SE Test P 
1.00 -0.3338 0.0596 -5.5967 <0.0001 -1.1157 0.0749 -14.9004 <0.0001 
1.47 -0.2977 0.0563 -5.2895 <0.0001 -1.0544 0.0773 -13.6413 <0.0001 
1.95 -0.3027 0.0550 -5.5048 <0.0001 -1.0383 0.0768 -13.5231 <0.0001 
2.42 -0.3067 0.0590 -5.1971 <0.0001 -1.0608 0.0781 -13.5901 <0.0001 
2.89 -0.3249 0.0591 -5.5020 <0.0001 -1.0817 0.0796 -13.5952 <0.0001 
3.37 -0.3234 0.0578 -5.5941 <0.0001 -1.0650 0.0802 -13.2871 <0.0001 
3.84 -0.3230 0.0568 -5.6869 <0.0001 -1.0709 0.0811 -13.2108 <0.0001 
4.32 -0.3383 0.0592 -5.7111 <0.0001 -1.0983 0.0800 -13.7285 <0.0001 
4.79 -0.2854 0.0601 -4.7467 <0.0001 -1.0958 0.0825 -13.2794 <0.0001 
5.26 -0.3178 0.0602 -5.2766 <0.0001 -1.0779 0.0799 -13.4905 <0.0001 
5.74 -0.3237 0.0564 -5.7421 <0.0001 -1.0428 0.0811 -12.8631 <0.0001 
6.21 -0.2817 0.0587 -4.7947 <0.0001 -1.0700 0.0816 -13.1177 <0.0001 
6.68 -0.3247 0.0580 -5.5948 <0.0001 -1.0396 0.0822 -12.6410 <0.0001 
7.16 -0.2809 0.0585 -4.8045 <0.0001 -1.0891 0.0838 -12.9958 <0.0001 
7.63 -0.3139 0.0604 -5.1940 <0.0001 -1.1010 0.0843 -13.0537 <0.0001 
8.11 -0.2912 0.0558 -5.2190 <0.0001 -1.0058 0.0835 -12.0474 <0.0001 
8.58 -0.3040 0.0565 -5.3760 <0.0001 -1.0581 0.0857 -12.3508 <0.0001 
9.05 -0.2913 0.0585 -4.9821 <0.0001 -1.0917 0.0842 -12.9649 <0.0001 
9.53 -0.3603 0.0627 -5.7482 <0.0001 -1.0652 0.0834 -12.7686 <0.0001 






Estimates and Standard Errors across 20 M Values for Karnof, Symptom, Treat and 
CD4 Variables in ACTG 175 for Noninformative Censoring 
M Estimates Standard Errors 
 Karnof Symptom Treat CD4 Karnof Symptom Treat CD4 
1.00 -0.1967 0.2342 -0.3490 -1.0675 0.0607 0.0567 0.0607 0.0738 
1.47 -0.1383 0.1895 -0.2699 -0.9844 0.0526 0.0494 0.0549 0.0815 
1.95 -0.0944 0.1451 -0.2288 -0.9046 0.0508 0.0479 0.0557 0.0969 
2.42 -0.0813 0.0853 -0.1260 -0.4431 0.0300 0.0288 0.0333 0.0874 
2.89 -0.0563 0.0531 -0.1332 -0.5269 0.0330 0.0331 0.0423 0.1314 
3.37 -0.0315 0.0664 -0.1283 -0.5098 0.0313 0.0324 0.0405 0.1075 
3.84 -0.0214 0.0450 -0.0709 -0.3310 0.0212 0.0216 0.0247 0.0674 
4.32 -0.0368 0.0940 -0.1076 -0.4079 0.0259 0.0306 0.0329 0.0921 
4.79 -0.0132 0.0468 -0.1269 -0.4651 0.0284 0.0282 0.0368 0.0987 
5.26 -0.0258 0.0546 -0.0795 -0.3590 0.0213 0.0217 0.0242 0.0699 
5.74 -0.0615 0.0951 -0.1115 -0.3753 0.0319 0.0337 0.0381 0.0972 
6.21 -0.0471 0.0766 -0.0709 -0.3450 0.0295 0.0333 0.0308 0.0978 
6.68 -0.0652 0.0689 -0.1370 -0.4916 0.0332 0.0347 0.0524 0.1649 
7.16 -0.0351 0.0652 -0.0572 -0.3501 0.0226 0.0249 0.0240 0.0772 
7.63 -0.0286 0.0996 -0.0921 -0.3656 0.0295 0.0316 0.0314 0.0843 
8.11 -0.0045 0.0928 -0.0695 -0.3459 0.0294 0.0314 0.0281 0.0764 
8.58 -0.0274 0.0499 -0.0606 -0.3242 0.0265 0.0271 0.0292 0.0927 
9.05 -0.0330 0.0378 -0.1041 -0.4988 0.0314 0.0326 0.0386 0.1184 
9.53 -0.0188 0.0697 -0.1096 -0.4303 0.0340 0.0378 0.0487 0.1428 






Test Statistics and P-values across 20 M Values for Karnof, Symptom, Treat and CD4 
Variables in ACTG 175 for Noninformative Censoring 
M Test Statistics P-values 
 Karnof Symptom Treat CD4 Karnof Symptom Treat CD4 
1.00 -3.2415 4.1281 -5.7495 -14.4636 0.0012 <0.0001 <0.0001 <0.0001 
1.47 -2.6284 3.8389 -4.9124 -12.0758 0.0086 0.0001 <0.0001 <0.0001 
1.95 -1.8580 3.0311 -4.1086 -9.3374 0.0632 0.0024 <0.0001 <0.0001 
2.42 -2.7090 2.9591 -3.7801 -5.0695 0.0067 0.0031 0.0002 <0.0001 
2.89 -1.7089 1.6035 -3.1484 -4.0097 0.0875 0.1088 0.0016 0.0001 
3.37 -1.0077 2.0473 -3.1652 -4.7429 0.3136 0.0406 0.0015 <0.0001 
3.84 -1.0087 2.0818 -2.8696 -4.9113 0.3131 0.0374 0.0041 <0.0001 
4.32 -1.4188 3.0721 -3.2718 -4.4277 0.1560 0.0021 0.0011 <0.0001 
4.79 -0.4652 1.6565 -3.4505 -4.7122 0.6418 0.0976 0.0006 <0.0001 
5.26 -1.2103 2.5146 -3.2871 -5.1358 0.2262 0.0119 0.0010 <0.0001 
5.74 -1.9280 2.8206 -2.9293 -3.8615 0.0539 0.0048 0.0034 0.0001 
6.21 -1.5939 2.3013 -2.2984 -3.5274 0.1110 0.0214 0.0215 0.0004 
6.68 -1.9602 1.9871 -2.6132 -2.9809 0.0500 0.0469 0.0090 0.0029 
7.16 -1.5581 2.6241 -2.3810 -4.5327 0.1192 0.0087 0.0173 <0.0001 
7.63 -0.9689 3.1520 -2.9362 -4.3388 0.3326 0.0016 0.0033 <0.0001 
8.11 -0.1536 2.9539 -2.4730 -4.5250 0.8779 0.0031 0.0134 <0.0001 
8.58 -1.0340 1.8442 -2.0759 -3.4978 0.3011 0.0651 0.0379 0.0005 
9.05 -1.0530 1.1605 -2.6932 -4.2114 0.2923 0.2459 0.0071 <0.0001 
9.53 -0.5539 1.8414 -2.2520 -3.0130 0.5797 0.0656 0.0243 0.0026 







Estimates and Standard Errors across 20 M Values for Karnof, Symptom, Treat and 
CD4 Variables in ACTG 175 for Informative Censoring 
M Estimates Standard Errors 
 Karnof Symptom Treat CD4 Karnof Symptom Treat CD4 
1.00 -0.1967 0.2342 -0.3490 -1.0675 0.0607 0.0567 0.0607 0.0738 
1.47 -0.1857 0.2156 -0.3127 -1.0200 0.0569 0.0536 0.0580 0.0746 
1.95 -0.1559 0.2002 -0.3125 -1.0053 0.0548 0.0520 0.0564 0.0750 
2.42 -0.1616 0.2283 -0.3231 -1.0235 0.0583 0.0551 0.0606 0.0761 
2.89 -0.1760 0.2130 -0.3362 -1.0422 0.0583 0.0539 0.0604 0.0783 
3.37 -0.1674 0.2171 -0.3363 -1.0299 0.0576 0.0541 0.0591 0.0777 
3.84 -0.1512 0.2257 -0.3371 -1.0366 0.0583 0.0548 0.0586 0.0789 
4.32 -0.1961 0.2176 -0.3584 -1.0656 0.0604 0.0559 0.0616 0.0783 
4.79 -0.2122 0.1940 -0.2984 -1.0515 0.0613 0.0565 0.0611 0.0811 
5.26 -0.1764 0.1871 -0.3312 -1.0447 0.0582 0.0551 0.0615 0.0788 
5.74 -0.1592 0.2193 -0.3451 -1.0178 0.0584 0.0544 0.0583 0.0792 
6.21 -0.1608 0.1984 -0.2999 -1.0497 0.0597 0.0558 0.0612 0.0803 
6.68 -0.1694 0.2001 -0.3411 -1.0045 0.0595 0.0546 0.0592 0.0802 
7.16 -0.1945 0.2003 -0.3023 -1.0661 0.0604 0.0566 0.0607 0.0806 
7.63 -0.1713 0.2249 -0.3225 -1.0590 0.0567 0.0536 0.0609 0.0825 
8.11 -0.1762 0.2009 -0.3074 -0.9850 0.0585 0.0538 0.0581 0.0802 
8.58 -0.1583 0.1823 -0.3162 -1.0235 0.0564 0.0530 0.0584 0.0838 
9.05 -0.2024 0.2294 -0.3110 -1.0637 0.0608 0.0575 0.0612 0.0825 
9.53 -0.2189 0.2226 -0.3878 -1.0319 0.0625 0.0588 0.0650 0.0811 






Test Statistics and P-values across 20 M Values for Karnof, Symptom, Treat and CD4 
Variables in ACTG 175 for Informative Censoring 
M Test Statistics P-values 
 Karnof Symptom Treat CD4 Karnof Symptom Treat CD4 
1.00 -3.2415 4.1281 -5.7495 -14.4636 0.0012 <0.0001 <0.0001 <0.0001 
1.47 -3.2621 4.0248 -5.3929 -13.6792 0.0011 0.0001 <0.0001 <0.0001 
1.95 -2.8432 3.8500 -5.5376 -13.4064 0.0045 0.0001 <0.0001 <0.0001 
2.42 -2.7696 4.1463 -5.3341 -13.4444 0.0056 <0.0001 <0.0001 <0.0001 
2.89 -3.0189 3.9535 -5.5625 -13.3162 0.0025 0.0001 <0.0001 <0.0001 
3.37 -2.9054 4.0113 -5.6897 -13.2598 0.0037 0.0001 <0.0001 <0.0001 
3.84 -2.5934 4.1231 -5.7556 -13.1307 0.0095 <0.0001 <0.0001 <0.0001 
4.32 -3.2478 3.8926 -5.8205 -13.6000 0.0012 0.0001 <0.0001 <0.0001 
4.79 -3.4648 3.4327 -4.8865 -12.9653 0.0005 0.0006 <0.0001 <0.0001 
5.26 -3.0316 3.3955 -5.3874 -13.2565 0.0024 0.0007 <0.0001 <0.0001 
5.74 -2.7284 4.0280 -5.9197 -12.8519 0.0064 0.0001 <0.0001 <0.0001 
6.21 -2.6944 3.5535 -4.9006 -13.0641 0.0071 0.0004 <0.0001 <0.0001 
6.68 -2.8489 3.6647 -5.7581 -12.5192 0.0044 0.0002 <0.0001 <0.0001 
7.16 -3.2203 3.5375 -4.9827 -13.2207 0.0013 0.0004 <0.0001 <0.0001 
7.63 -3.0219 4.1981 -5.2982 -12.8412 0.0025 <0.0001 <0.0001 <0.0001 
8.11 -3.0116 3.7334 -5.2926 -12.2856 0.0026 0.0002 <0.0001 <0.0001 
8.58 -2.8085 3.4378 -5.4153 -12.2076 0.0050 0.0006 <0.0001 <0.0001 
9.05 -3.3304 3.9869 -5.0835 -12.8886 0.0009 0.0001 <0.0001 <0.0001 
9.53 -3.5042 3.7837 -5.9702 -12.7288 0.0005 0.0002 <0.0001 <0.0001 
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The present study developed an easy-to-use code for interval-censored survival 
data with both fixed and time-dependent covariates. Extensive simulations were 
conducted to investigate the robustness of the interval-censored survival analysis with 
inaccurate time bounds and time-dependent covariates, particularly under 
noninformative censoring and informative censoring. Moreover, a real data analysis 
on the ACTG 175 data was conducted to investigate the robustness of findings under 
different variations of time bounds. 
The likelihood approach was used to draw inferences about the unknown 
parameters. The parameter estimator was the maximizer of the log-likelihood function 
and was asymptotically normal. The R package, numDeriv, was used to calculate the 
Hessian matrix of the negative log-likelihood. The estimated variance was the 
diagonal of the inverse of the Hessian matrix and the standard errors of the estimates 
equaled the square root of the estimated variance. The confidence intervals were 
constructed using estimates plus and minus 1.96 times standard errors. 
In the simulations, the parameter estimates were obtained, and then the bias, 
the standard error, the mean squared error, and the coverage probability of 95% 
confidence interval for each parameter were calculated and reported for each of the 20 
M values for the simulated dataset including both fixed and time-dependent covariates. 





censoring, parameter estimates as well as coverage probability were more robust 
against change across M values for 𝛾1, 𝛾2, and 𝜂 than for 𝜃, 𝜅, and 𝛼, which were not 
that robust against change across M values. The parameter estimates and coverage 
probability were also demonstrated for each of the 20 M values for the simulated 
dataset including only fixed covariates. The findings demonstrated that for both 
noninformative censoring and informative censoring, parameter estimates as well as 
coverage probability were more robust against change across M values for 𝛾1 and 𝛾2 
than for 𝜃, 𝜅, and 𝛼, which were not that robust against change across M values. 
 In the scenarios considered in this simulation study, for both noninformative 
censoring and informative censoring, the scale and shape parameters (𝜃, 𝜅, and 𝛼) 
changed as M value changed, so parameter estimates and coverage probability for 𝜃, 
𝜅, and 𝛼 were not robust against change across M values. However, since 
noninformative censoring is not related to survival time but informative censoring is 
related to survival time, the change of scale and shape parameters (𝜃, 𝜅, and 𝛼) was 
not as severe as that for informative censoring. In addition, the informative censoring 
scenario considered in this study has no strong relationship with fixed covariates and 
time-dependent covariates, thus for informative censoring, parameter estimates and 
coverage probability for 𝛾1, 𝛾2, and 𝜂 were also robust against change across M 
values. 
In the real data analysis, the estimates, standard errors, and p-values across 20 
M values for the fixed covariate, treat, and the time-dependent covariate, cd4, in 
ACTG 175 were obtained. The findings demonstrated that for noninformative 





against change across M values; for informative censoring, the estimates as well as the 
p-values for treat and cd4 were more robust against change across M values. The 
estimates for treat and cd4 were all negative and significant for both noninformative 
censoring and informative censoring, which indicated longer survival time and event 
occurred later. The estimates under informative censoring were most robust against 
change across M values, which was consistent with the findings in the simulation 
study and worth further investigation.  
The real data analysis in this study also included some more covariates. The 
estimates, standard errors, and p-values across 20 M values were obtained for the fixed 
covariates, treat, karnof, and symptom, and the time-dependent covariate, cd4. The 
findings for this analysis when more covariates were included were compared with the 
findings for the analysis when only treat and cd4 were used. The results for treat and 
cd4 in this analysis were very similar to those in the analysis when only treat and cd4 
were used. 
This study was the first to develop the code for interval-censored survival data 
with both fixed and time-dependent covariates, and was the first to investigate the 
robustness of the interval-censored survival analysis under inaccurate time bounds. 
This study contributed to the research literature about the topic and contributed to the 
methodology, procedures, and analysis of future survival studies examining the similar 
topic.  
This project used ACTG 175 as the real data and was an illustration of how to 
evaluate the robustness of findings under inaccurate time bounds. Similar procedures 





analyzed clinical trial data and included one time-dependent covariate in the analysis. 
Future studies can include more time-dependent covariates and can be extended to 
other areas, such as the financial, accounting, and marketing areas; for example, be 
used for bankruptcy prediction and credit default prediction. What’s more, this study 
selected covariates that were included in the real data analysis based on previous 
studies analyzing ACTG 175 data (e.g., Hammer et al., 1996; Huang & Zhang, 2008; 
Scharfstein & Robins, 2002; Song et al., 2002; Song & Ma, 2008; Song & Wang, 
2017; Wen, 2012; Wen & Chen, 2014). Future studies can use automatic variable 
selection methods such as forward regression, backward regression, stepwise 
regression, and LASSO (e.g., Tibshirani,1996), in order to select the best subset of 
predictors for the analysis. In addition, for interval-censored data of a large number of 
observations, future studies can use a possible approach, the divide and conquer 
strategy, to handle the data. For example, for the simulated data with 500000 
observations, the data can be divided into 500 blocks and the parameter estimates and 
their variance within each block can be calculated. Finally, the 500 results will be 
merged into one.  
Besides, future studies may include joint models for longitudinal and time-to-
event data which bring these two data types together into a single model so that one 
can infer the association between the longitudinal biomarker and time to event to 
better examine the treatment effects and reduce bias in estimates of the treatment 
effects. One example of the joint model can be described as follows.  
We can utilize subject-specific random effects to account for the possible 





two models; one for the gap time between adjacent visits, and the other for the event 
time. As an illustration, we can assume that the hazard function for the gap time 











where the parameter vector 𝜔𝜏 = (𝜃𝜏, 𝛾𝜏, 𝜅𝜏, 𝛼𝜏 , 𝜂𝜏, 𝜎𝜏
2)𝑇; 𝜁𝑖 is random effects for the 
ith subject, which is assumed to be distributed as 𝑁(0, 𝜎𝜏
2). The corresponding 
probability density function is 
𝑓𝜏,𝑖(𝑡; 𝜔𝜏) = 𝜆𝜏,𝑖(𝑡; 𝜔𝜏)𝑒
− ∫ 𝜆𝜏,𝑖(𝑠;𝜔𝜏) 𝑑𝑠
𝑡
0 . 











where the parameter vector 𝜔𝑋 = (𝜃𝑋 , 𝛾𝑋, 𝜅𝑋 , 𝛼𝑋 , 𝜂𝑋 , 𝜌𝑋)
𝑇. The corresponding 
probability density function is 
𝑓𝑋,𝑖(𝑡; 𝜔𝑋) = 𝜆𝑋,𝑖(𝑡; 𝜔𝑋)𝑒
− ∫ 𝜆𝑋,𝑖(𝑠;𝜔𝑋) 𝑑𝑠
𝑡
0 , 
and the cumulative distribution function is 
𝐹𝑋,𝑖(𝑡; 𝜔𝑋) = 1 − 𝑒
− ∫ 𝜆𝑋,𝑖(𝑠;𝜔𝑋) 𝑑𝑠
𝑡
0 . 

















− 𝜏𝑖,𝑗; 𝜔𝜏) 𝜙(𝜁𝑖; 𝜎𝜏
2) 𝑑𝜁𝑖} , 
where 𝜙(𝜁𝑖; 𝜎𝜏
2) is the density function of 𝑁(0, 𝜎𝜏
2). We can also test for 
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